Moderna

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. 

CEO
Stéphane Bancel
CEOStéphane Bancel
Employees
5,800
Employees5,800
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
5,800
Employees5,800

MRNA Key Statistics

Market cap
12.10B
Market cap12.10B
Price-Earnings ratio
-3.84
Price-Earnings ratio-3.84
Dividend yield
Dividend yield
Average volume
10.93M
Average volume10.93M
High today
$32.21
High today$32.21
Low today
$30.32
Low today$30.32
Open price
$30.78
Open price$30.78
Volume
13.70M
Volume13.70M
52 Week high
$48.92
52 Week high$48.92
52 Week low
$22.28
52 Week low$22.28

Stock Snapshot

The current Moderna(MRNA) stock price is $30.89, with a market capitalization of 12.1B. The stock trades at a price-to-earnings (P/E) ratio of -3.84.

During the trading session on 2025-12-19, Moderna(MRNA) shares reached a daily high of $32.21 and a low of $30.32. At a current price of $30.89, the stock is +1.9% higher than the low and still -4.1% under the high.

Trading activity shows a volume of 13.7M, compared to an average daily volume of 10.93M.

The stock's 52-week range extends from a low of $22.28 to a high of $48.92.

The stock's 52-week range extends from a low of $22.28 to a high of $48.92.

MRNA News

Seeking Alpha 19h
Moderna granted up to $54.3M from CEPI for bird flu vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership supporting vaccine studies, has agreed to invest up to $54.3M to support a Phas...

Moderna granted up to $54.3M from CEPI for bird flu vaccine
Simply Wall St 4d
Moderna Is Up 5.3% After EU Panel Backs Next-Gen COVID Shot mNEXSPIKE - What's Changed

Earlier this week, Moderna received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use recommending EU marke...

Moderna Is Up 5.3% After EU Panel Backs Next-Gen COVID Shot mNEXSPIKE - What's Changed
TipRanks 4d
Moderna saus CHMP adopts positive opinion for mNEXSPIKE

Moderna (MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketi...

Analyst ratings

62%

of 26 ratings
Buy
19.2%
Hold
61.5%
Sell
19.2%

More MRNA News

Simply Wall St 5d
Moderna: Reassessing Valuation After Recent Share Price Rebound and Stabilizing Revenue Trends

Moderna (MRNA) has been drifting lower this year, even as its pipeline and revenue trends show some signs of stabilization. That disconnect is what has put the...

Moderna: Reassessing Valuation After Recent Share Price Rebound and Stabilizing Revenue Trends

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.